Jerry Yang serves as Founding Partner at AME Cloud Ventures. Yang also serves as Special Partner at Neotribe Ventures. He serves as Investor of BirdEye. He also serves as an Independent Director at Workday and Advisor at Radius. He is the Founding Partner at AME Cloud Ventures. He serves as Board Observer and Senior Advisor at Didi Kuaidi. Since March 2012, he has worked with and invests in technology entrepreneurs as the founding partner of AME Cloud Ventures, his innovation investment firm. He is also a co-founder of Yahoo! Inc., where he served as a director from March 1995 to January 2012, and as Chief Executive Officer from June 2007 to January 2009. He also led Yahoo!'s investments in Yahoo Japan and Alibaba Group Holding Limited, and he is a currently a director of Alibaba Group, where he has served on the board from October 2005 to January 2012 and from September 2014 to the present. He is also a director of Lenovo, Inc. where he has served on the board since November 2014. From July 2000 to November 2012, he was a member of Cisco Systems, Inc.'s Board of Directors, and he was a director of Yahoo! Japan from January 1996 to January 2012. He also is a director of various private companies and foundations. He received a B.S. and M.S. in Electrical Engineering from Stanford University, where he served as Vice Chair of the Board of Trustees from June 2005 until September 2016. He is also an Angel Investor. He serves as Board Member at Docker
Tony Corbin
Investing in BioTech • Businesses Solutions ...
Menlo Park , San Fran..., U.S.A. - Israel - Europe: Germany, United Kingdom, France, Italy, Spain, Poland, Romania, Netherlands, Belgium, Czech Republic, Greece, Portugal, Sweden, Hungary, Austria, Switzerland, Denmark, Finland, Slovakia, Norway, Ireland, Luxembourg, Malta, Icelan
Previous Investments
• Vayyar Imaging:
$109000000 (Later stage VC)
• VDOO:
$57000000 (Later stage VC)
• Cloudleaf:
$26000000 (Later stage VC)
• Fakespot:
(Series A)
• Fakespot:
$4000000 (Series A)
• Sumatra:
$2000000 (Seed)
• MRGN:
(Pre Seed)
• MRGN:
(Pre-Seed)
• Ash Wellness:
$3000000 (Seed)
• Ash Wellness:
(Seed+)
• AppliedXL:
$4000000 (Seed)
• AssetDash:
(Pre Seed)
• Tabula:
$3000000 (Pre Seed)
• Naya:
$6000000 (Seed)
• Thorium Data:
$100000 (Pre Seed)
• OpenAxis:
$2000000 (Pre Seed)
• CACTIVATE:
(Pre Seed)
• Grin Gaming:
(Seed)
• Grin Gaming:
(Seed)
• Docket:
(Seed)
• Ask Vera:
(Seed)
• UrsaLeo:
(Seed+)
• Cactivate:
(Pre-Seed)
• Clearforce:
(Seed)
• Paragon Intel:
(Seed+)
• Intrro:
(Seed)
• Bazze:
(Pre-Seed)
• Asset Dash:
(Pre-Seed)
• Extend:
$16000000 (Series A)
• OneCell Diagnostics:
$16000000 (Series A)
• Finicast:
$13000000 (Seed)
• Very Good Ventures:
$3000000 (Series A)
• Very Good Ventures:
$3000000 (Series A)
• Prellis Biologics:
$35000000 (Series C)
• Prellis Biologics:
$15000000 (Series B)
• Biomason:
$65000000 (Series C)
• Home Delivery Service (HDS Global):
$5000000 (Series Unknown)
• Rizzle:
$17000000 (Convertible Note)
• EnTribe:
$3000000 (Seed)
• Atonarp:
$50000000 (Series D)
• Atonarp:
$2000000 (Series B)
• Atonarp:
$4000000 (Series A)
• Boom Supersonic:
$50000000 (Series C)
• Extend, Inc.:
$16000000 (Series A)
• Quartic.ai:
$2000000 (Seed)
• Globality:
$27000000 (Series B)
• Globality:
$10000000 (Series A)
• BangDB:
(Seed)
• Reaction:
$10000000 (Series A)
• Reaction:
$2000000 (Seed)
• Shipster:
(Seed)
• H2O.ai:
$9000000 (Series A)
• Trove:
$5000000 (Series A)
• FUTR Corp.:
$5000000 (Seed)
• Yellowsmith:
$850000 (Seed)
• Printi:
$1000000 (Series A)
• GoPro:
$88000000 (Series A)
Tony Corbin
Menlo Park - San Francisco Bay Area - California, U.S.A. - Israel - Europe: Germany, United Kingdom, France, Italy, Spain, Poland, Romania, Netherlands, Belgium, Czech Republic, Greece, Portugal, Sweden, Hungary, Austria, Switzerland, Denmark, Finland, Slovakia, Norway, Ireland, Luxembourg, Malta, Icelan
Riverwood Capital is a globally-focused private equity firm that invests in high-growth businesses in the technology and services industries, across a variety of verticals and geographies. Riverwood has offices in Menlo Park, CA and New York, NY and currently has more than 20 investments in North America, Latin America and Asia. The firm's current fund has $780 million of committed capital. The final fund close was in April 2011. Riverwood invests in mid-market technology and technology enabled products and services. The firm defines mid-market as approximately $100-$500 million in revenue for product companies, and approximately $25-$150 million in revenue for software and services. Riverwood occasionally invests outside these ranges. Riverwood invests on a global basis, having already invested in the U.S., Israel, Argentina, Chile, and Brazil. The firm's normal investment size ranges from $25-75 million.
Anton Levy serves as Managing Director and Global Head of Internet & Technology at General Atlantic. He heads General Atlantic's global Internet & Technology practice and serves on the firm's Investment and Executive Committees. Since joining GA in 1998, he has worked on investments around the globe and across various sectors. Over the last 8 years, he has focused on building out GA's global Internet & Technology sector. He is currently a director of Squarespace, SnapAV, Acumen Brands, Klarna, Red Ventures, Gilt Groupe and Web.com, and manages a number of GA's other investments in the Internet, marketing services and media areas. He is a former director of AKQA, Dice Holdings, Mercado Libre, Network Solutions and Zantaz Corporation. He also led the firm's investments in Alibaba Group and Facebook. Before joining GA, Anton was an investment banker with Morgan Stanley & Co., where he worked with the firm's technology clients. Anton is involved with several educational and not-for-profit organizations, including currently serving as Chairman of Streetwise Partners and as a trustee of WNYC (New York Public Radio) and University of Virginia's Endowment (UVIMCO). Anton earned his B.S. from the University of Virginia, with degrees in Finance and Computer Science, and his M.B.A. from Columbia University Graduate School of Business, graduating both with highest honors. Levy also serves as Board Member at A Place for Mom.
Venrock invests in technology and healthcare. Individual focus areas: Biotechnology, Diagnostics, Genomics, Healthcare IT, Medical Devices. Prefers: category kings + big risk element
Dalton Caldwell
Investing in Software (Web Marketplace Saas..) &b...
Eduardo Saverin is a Co-Founder and serves as Partner at B Capital Group. He is a Co-Founder of Facebook. He also co-founded Velos Partners, a private equity firm based in Los Angeles and serves as its Chairman. He serves on the board of Carro, Connexions Asia and Ninja Van. He also serves as Advisor at Golden Gate Ventures.
Jenny Rooke
Investing in BioTech • Pharmaceutical (& Med...
San Francisco Bay Are..., U.S.A.
Previous Investments
• BrightSpec:
$18000000 (Series C)
• Bond Pet Foods:
$18000000 (Series A)
• Meiogenix:
$12000000 (Series A)
• InterVenn:
$200000000 (Series C)
• InterVenn:
$34000000 (Series B)
• InterVenn:
$9000000 (Series Unknown)
• Ionpath:
$18000000 (Series B)
• Ionpath:
(Series A)
• Ionpath:
(Seed)
• Tropic Biosciences:
$29000000 (Series B)
• Intabio:
$18000000 (Series B)
• Intabio:
$10000000 (Series A)
• Intabio:
$2000000 (Seed)
• NanoCellect Biomedical:
$10000000 (Series B)
• Akadeum Life Sciences:
$2000000 (Series Unknown)
Therapeutics;
Digital health (pure digital, no wet biology or chem);
Uncapped convertible notes
Dr. Jenny Rooke is the Founder and serves as Managing Director at Genoa Ventures. She is an early-stage venture capital investor. She is the Founder and serves as a Managing Director at 5 Prime Ventures. She also served as a Venture Partner at F-Prime Capital Partners (healthcare) and Anterra Capital (agriculture). She brings a combination of strategy, operating, and investing experience to her work with early stage life science companies, specializing in research tools, diagnostics, and synthetic biology. Jenny's investing experience includes roles in the Bill & Melinda Gates Foundation's Global Health Discovery group, and at F-Prime Capital, where she served her Kauffman Fellowship. Dr. Rooke held multiple executive positions at U.S. Genomics, a venture-backed biotech start-up advancing single molecule detection technologies for diagnostics, biodefense, and research. Previously, Dr. Rooke was a management consultant with McKinsey & Co., where she advised leading pharmaceutical and biotech companies on business strategy. Dr. Rooke earned her Ph.D. in genetics from Yale University and her B.S. in physics from Georgia Tech. She is also a Board Member at Intabio.
How to connect with Angel Investors in the BioTech industry?
In the BioTech industry, angel investors such as Esther Dyson, Vinod Khosla, and Steve Jurvetson are prominent figures. These investors focus on startups offering innovative solutions in biotechnology, genomics, and medical research. Esther Dyson, an entrepreneur and investor, looks for biotech startups that have the potential to make significant advancements in healthcare and medicine. Vinod Khosla, founder of Khosla Ventures, invests in high-impact biotech companies with disruptive technologies. Steve Jurvetson, a co-founder of Future Ventures, seeks out startups that push the boundaries of biological science and innovation. To connect with these investors, attend biotech conferences, medical expos, and networking events such as BIO International Convention, JP Morgan Healthcare Conference, and SynBioBeta. Utilize platforms like AngelList and LinkedIn to identify and reach out to potential investors. When pitching, emphasize how your biotech solution addresses key challenges in healthcare and medical research, such as developing new therapies, improving diagnostic accuracy, or advancing genomic research. Highlight any traction you’ve gained, such as partnerships with research institutions, successful clinical trials, or regulatory approvals. Building relationships through initial informal meetings or discussions at industry panels can help establish trust with these investors. Demonstrating the impact of your technology through case studies or clinical results can also add credibility. Personalize your outreach by referencing the investor’s previous investments and explaining how your venture aligns with their interests. Demonstrating a sustainable business model with clear revenue streams, such as licensing, product sales, or research grants, will further strengthen your pitch. Leveraging endorsements or case studies from biotech experts can also enhance your credibility.
Case Studies: Successful Funding Rounds with Angel Investors on Angels Partners
Exotic Orange & Angels Partners: Turning Financial Simplicity Into Investment Success
